The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women by Parish, Sharon J. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The International Society for the Study of Women's Sexual Health Process of Care for
the Identification of Sexual Concerns and Problems in Women
Parish, Sharon J.; Hahn, Steven R.; Goldstein, Sue W.; Giraldi, Annamaria; Kingsberg, Sheryl
A.; Larkin, Lisa; Minkin, Mary Jane; Brown, Vivien; Christiansen, Kristin; Hartzell-Cushanick,
Rose; Kelly-Jones, Alyse; Rullo, Jordan; Sadovsky, Richard; Faubion, Stephanie S.
Published in:
Mayo Clinic Proceedings
DOI:
10.1016/j.mayocp.2019.01.009
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Parish, S. J., Hahn, S. R., Goldstein, S. W., Giraldi, A., Kingsberg, S. A., Larkin, L., ... Faubion, S. S. (2019). The
International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual
Concerns and Problems in Women. Mayo Clinic Proceedings, 94(5), 842-856.
https://doi.org/10.1016/j.mayocp.2019.01.009
Download date: 03. Feb. 2020
CLINICAL PRACTICE GUIDELINESFor editorial
comment, see
page 739
From the Department of
Medicine and Department of
Psychiatry, Weill Cornell
Afﬁliations continued at
the end of this article.
842
www.mayoclinicproce
DownloadeThe International Society for the Study of
Women’s Sexual Health Process of Care for
the Identiﬁcation of Sexual Concerns and
Problems in Women
Sharon J. Parish, MD; Steven R. Hahn, MD; Sue W. Goldstein, BA;
Annamaria Giraldi, MD, PhD; Sheryl A. Kingsberg, PhD; Lisa Larkin, MD;
Mary Jane Minkin, MD; Vivien Brown, MDCM; Kristin Christiansen, MD;
Rose Hartzell-Cushanick, PhD; Alyse Kelly-Jones, MD; Jordan Rullo, PhD;
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Sexual problems are common in women of all ages. Despite their frequency and impact, female sexual
dysfunctions (FSDs) are often unrecognized and untreated in clinical settings. In response, the In-
ternational Society for the Study of Women’s Sexual Health convened a multidisciplinary, interna-
tional expert panel to develop a process of care (POC) that outlines recommendations for
identiﬁcation of sexual problems in women. This POC describes core and advanced competencies in
FSD for clinicians who are not sexual medicine specialists and serve as caregivers of women and,
therefore, is useful for clinicians with any level of competence in sexual medicine. The POC begins
with the expectation of universal screening for sexual concerns, proceeds with a 4-step model (elic-
iting the story, naming/reframing attention to the problem, empathic witnessing of the patient’s
distress and the problem’s impact, and referral or assessment and treatment) that accommodates all
levels of engagement, and delineates a process for referral when patients’ needs exceed clinician
expertise. Distressing problems related to desire, arousal, and orgasm affect 12% of women across the
lifespan. Low desire is the most common sexual problem, but sexual pain and other less common
disorders of arousal and orgasm are also seen in clinical practice. Screening is best initiated by a
ubiquity statement that assures the patient that sexual concerns are common and can be revealed.
Patient-centered communication skills facilitate and optimize the discussion. The goal of the POC is to
provide guidance to clinicians regarding screening, education, management, and referral for women
with sexual problems.
ª 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2019;94(5):842-856S exual health concerns are commonamong women. When a sexual prob-lem causes signiﬁcant distress and
impairment, this may be diagnosed as a sex-
ual dysfunction. Female sexual dysfunctions
(FSDs) are substantially undetected and un-
addressed in primary care settings and are
often undertreated even when they are
recognized. Clinicians who do not specialize
in sexual medicine may not feel comfortableMayo Clin Proc. n May 201
edings.org n ª 2019 Mayo Foundation for Medical Education and Re
under the CC BY-NC-N
d for Anonymous User (n/a) at BS - University of Copenhagen from C
For personal use only. No other uses without permission. Copyright ©detecting, managing, and referring women
for sexual health concerns. Reasons for the
failure to detect and treat FSDs include def-
icits in speciﬁc knowledge and skills, such
as those required to engage women in effec-
tive and efﬁcient discussion about their
sexual health, and awareness of the availabil-
ity and efﬁcacy of treatments.1
These recommendations represent the
consensus of experts on the competencies9;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
search. Published by Elsevier Inc. This is an open access article
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
linicalKey.com by Elsevier on November 14, 2019.
2019. Elsevier Inc. All rights reserved.
POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENneeded by clinicians who serve as primary
caregivers for women (eg, gynecology, fam-
ily medicine, internal medicine), as well as
any nonsexual medicine specialists (eg, car-
diology, rheumatology, dermatology). The
recommendations describe a process of care
(POC) for clinicians at any level of compe-
tence in sexual medicine by delineating a
strategy for referral when patients’ needs
exceed the clinician’s level of expertise or
engagement. The POC begins with the
expectation of universal screening for sexual
concerns and problems and proceeds with a
4-step model that accommodates all levels of
engagement. This consensus recommenda-
tion consists of a succinct presentation of
the scope and nature of FSDs, and the skills
and knowledge required to screen for sexual
problems in women and to execute the
4-step model of care.METHODS
The International Society for the Study of
Women’s Sexual Health (ISSWSH) assem-
bled an international, multidisciplinary
panel consisting of experts in sexual medi-
cine, women’s health, gynecology, internal
medicine, and family medicine. The expert
panel reviewed and discussed strategies to
deﬁne the basic competencies for identiﬁca-
tion and management of FSD and to describe
more advanced competencies for clinicians
with particular interest in sexual medicine.
Consensus was developed for recommenda-
tions for identiﬁcation of sexual health prob-
lems in women. There was no industry
involvement in any part of the process.MANAGEMENT OF SEXUAL DYSFUNCTION
IN WOMEN IS A PRIORITY
Primary care is characterized by longitudinal
relationships that provide an ideal opportu-
nity to discuss and resolve the multifactorial
issues that may affect sexual health.2,3 A
clinician who has spent time getting to
know the patient in the context of their fam-
ily and social environment can evaluate the
many potential causes of sexual dysfunction
and provide the follow-up needed to ensure
resolution of problems.Mayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
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For personal use only. No other uses withouMost patients want the opportunity to
discuss sexual health concerns with their
clinician,4,5 and they prefer that the clinician
bring up the topic.1,6-8 When sexual health
issues are discussed, especially in a patient-
centered style that demonstrates interest,
empathy, and a nonjudgmental attitude,
patient satisfaction with the interaction can
increase, and the relationship between the
patient and the clinician is strengthened.9,10
The value of discussions about sexual
health is high for patients throughout the
lifespan. A survey showing women’s engage-
ment in sexual activity over the previous 3
months revealed 65% to 70% at ages 18 to
49 years, 46% at ages 50 to 59 years, and
20% at ages 60 to 94 years.11 Married women
are more likely to be sexually active, espe-
cially with increasing age.11 Satisfaction
with sex is a major quality of life indicator.12
NOMENCLATURE
Female sexual dysfunctions have distinct
classiﬁcations, deﬁnitions, and diagnostic
criteria, as described in the Diagnostic and
Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5),13 the Fourth International
Consultation on Sexual Medicine (ICSM),14
the ISSWSH nomenclature,15 and the Inter-
national Classiﬁcation of Diseases and Related
Health Problems (ICD). The 11th Revision of
the ICD contains a new chapter on condi-
tions related to sexual health.16 The ICSM
and the ICD classify these issues as sexual
dysfunctions, and the ISSWSH uses the term
sexual disorders, consistent with the DSM
schema.15 In this POC, the term female sex-
ual dysfunction is used.
Sexual dysfunctions manifest as chronic
sexual symptoms related to sexual pain and
the 3 phases of the sexual response cycle:
desire, arousal, and orgasm. The FSDs are
deﬁned in Table 1.14,15,17 Normal varia-
tions in sexual function are distinguished
from FSDs by their persistence for a mini-
mum of 3 months, occurrence with at least
75% of sexual experiences, and their asso-
ciation with sexually related personal
distress.18 Female sexual dysfunction may
be lifelong or acquired after a period of
normal functioning and may be situational6/j.mayocp.2019.01.009 843
ity of Copenhagen from ClinicalKey.com by Elsevier on November 14, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
TABLE 1. ISSWSH and ICSM FSDs: Nomenclature and Deﬁnitions
Hypoactive sexual desire disorder
Manifests as any of the following for a minimum of 6 mo:
d Lack of motivation for sexual activity as manifested by either:
B Reduced or absent spontaneous desire (sexual thoughts or fantasies)
B Reduced or absent responsive desire to erotic cues and stimulation or inability to maintain desire or interest through sexual activity
d Loss of desire to initiate or participate in sexual activity, including behavioral responses such as avoidance of situations that could lead to sexual
activity, that is not secondary to sexual pain disorders
AND is combined with clinically signiﬁcant personal distress that includes frustration, grief, incompetence, loss, sadness, sorrow, or worry.
Female sexual arousal disorder
Female cognitive arousal disorder
d Characterized by the distressing difﬁculty or inability to attain or maintain adequate mental excitement associated with sexual activity as manifested by
problems with feeling engaged or mentally turned on or sexually aroused, for a minimum of 6 mo.
Female genital arousal disorder
d Characterized by the distressing difﬁculty or inability to attain or maintain adequate genital response, including vulvovaginal lubrication, engorgement
of the genitalia, and sensitivity of the genitalia associated with sexual activity, for a minimum of 6 mo.
d Disorders related to:
B Vascular injury or dysfunction
and/or
B Neurologic injury or dysfunction
Persistent genital arousal disorder
d Characterized by the persistent or recurrent, unwanted or intrusive, distressing feelings of genital arousal or being on the verge of orgasm (genital
dysesthesia), not associated with concomitant sexual interest, thoughts, or fantasies for a minimum of 6 mo.
May be associated with:
B Limited resolution, no resolution, or aggravation of symptoms by sexual activity with or without aversive or compromised orgasm
B Aggravation of genital symptoms by certain circumstances
B Despair, emotional lability, catastrophization, or suicidality
d Inconsistent evidence of genital arousal during symptoms
Female orgasm disorders
d Characterized by the persistent or recurrent, distressing compromise of orgasm frequency, intensity, timing, or pleasure associated with sexual activity
for a minimum of 6 mo:
B Frequency: orgasm occurs with reduced frequency (diminished frequency of orgasm) or is absent (anorgasmia).
B Intensity: orgasm occurs with reduced intensity (muted orgasm).
B Timing: orgasm occurs either too late (delayed orgasm) or too early (spontaneous or premature orgasm) than desired by the woman.
B Pleasure: orgasm occurs with absent or reduced pleasure (anhedonic orgasm, pleasure dissociative orgasm disorder).
Female orgasmic illness syndrome
d Characterized by the peripheral or central aversive symptoms that occur before, during, or after orgasm not related, per se, to a compromise of
orgasm quality.
Genitopelvic pain penetration dysfunction
Persistent or recurrent difﬁculties with 1 of the following:
d Vaginal penetration during intercourse
d Marked vulvovaginal or pelvic pain during genital contact
d Marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or as a result of genital contact
d Marked hypertonicity or overactivity of pelvic ﬂoor muscles with or without genital contact
FSD ¼ female sexual dysfunction; ICSM ¼ International Consultation on Sexual Medicine; ISSWSH ¼ International Society for the Study of Women’s Sexual Health.
Modiﬁed from McCabe et al14 and Parish et al.15,17
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generalized (present in all situations); and
related distress is characterized as mild,
moderate, or severe. Women mayMayo Clin Proc. n May 201
d for Anonymous User (n/a) at BS - University of Copenhagen from C
For personal use only. No other uses without permission. Copyright ©experience problems in multiple aspects
of their sexual response, thus FSDs may
be concurrent. The etiology of FSD is often
multifactorial and includes biological,9;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
www.mayoclinicproceedings.org
linicalKey.com by Elsevier on November 14, 2019.
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POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENpsychological, interpersonal, and sociocul-
tural risk factors and contributors15; ICD-
11 terms these as etiological qualiﬁers.16
The female sexual response cycle occurs in
2 distinguishable patterns. In the traditional
linear model, “spontaneous” desire for sexmo-
tivates initiation of sexual activity, which then
leads to arousal and orgasm. In the alternative,
circular model, sexual activity may be initiated
by motives other than desire for sex, for
example, a desire for intimacy; “responsive”
sexual desire occurs only after the arousal pro-
duced by the stimulation of sexual activity.19
Assessment of sexual desire in women should
evaluate the presence or absence of both spon-
taneous and responsive desire.
Female sexual desire and arousal disor-
ders were separated into 2 distinct categories
in earlier iterations of the DSM. The ratio-
nale for merging these categories in the
DSM-5 included the co-occurrence of desire
and arousal problems; the challenge of dis-
tinguishing between spontaneous desire
and responsive desire and distinguishing
sexual desire from other motivations for sex-
ual activity; and the relatively low reporting
of sexual fantasy in women.20-22 However,
based on substantial observational, clinical
sample, registry, and treatment outcome
data, experts have recommended maintain-
ing separate categories of hypoactive sexual
desire disorder (HSDD) and female sexual
arousal disorder.14,15
In theDSM-5, dyspareunia and vaginismus
were alsomerged into a single category: genito-
pelvic pain penetration disorder. The ICSM
version of genitopelvic pain penetration
dysfunction is deﬁned in Table 1. Sexual pain
can occur with initial penetration or deep
thrusting or with noncoital sexual activities.
Women may also have persistent vulvar pain
or pain at the vulvar vestibule with provoca-
tion, known as provoked vestibulodynia.23
Whereas desire, arousal, and orgasm dif-
ﬁculties and sexual pain concerns are more
commonly seen in clinical practice, persis-
tent genital arousal disorder, pleasure disso-
ciative orgasm disorder, and female orgasmic
illness syndrome are rare but very distressingMayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Univers
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their characteristics and impact (Table 1).15
Sexual distress is a crucial element in the
deﬁnition and for the diagnosis of an FSD.
Distress is described as bother, concern,
unhappiness, frustration, anger, or hopeless-
ness. It can manifest as distressing behavior
such as reduced or absent initiation of sexual
activity, avoidance of sexual situations, or
participation in sexual activity without
desire for it. Personal distress can be related
to the woman’s own sexual problem or to the
potential effect on her partner and their
relationship.24,25
EPIDEMIOLOGY
A broad range of sexual health concerns is
common among women of all ages.26-28
When personal distress is included in the deﬁ-
nition, FSD is less prevalent than the overall
rates of sexual problems. Sexual problems in
women are more prevalent with increasing
age, but sexual distress decreases with age,
making the prevalence of FSD approximately
stable throughout the life span of women.
The Prevalence of Female Sexual Prob-
lems Associated With Distress and Determi-
nants of Treatment Seeking (PRESIDE)
study29 involving 31,581 US women aged 18
to 102 years found that, overall, 44%
reported any sexual problem (desire, arousal,
orgasm). Low desire was the most common
problem reported by 39% of women, low
arousal by 26%, and orgasm problems by
21%.When distress was combinedwith a sex-
ual problem, 12% experienced any distressing
sexual problem (10% low desire, 5.5% low
arousal, 4.7% orgasm problems).29 A distress-
ing sexual problem was more common in
women aged 45 to 64 years (14.8%) than in
younger (10.8%) or older (8.9%) women.
Similar patterns have been shown in other
larger-scale studies.30,31
In the PRESIDE study, of the more than
1000 women (approximately one-third)
who sought formal help for sexual problems,
nearly 90% sought help from their gynecolo-
gist or primary care physician.32 More than
half of the women who sought help did so6/j.mayocp.2019.01.009 845
ity of Copenhagen from ClinicalKey.com by Elsevier on November 14, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Core level treatment
• Education about effects of aging, sexual adverse
   effects of medication, etc
• Personal lubricants, moisturizers, and local hormone
   therapy for dyspareunia secondary to genitourinary
   syndrome of menopause
• Importance of foreplay, nonpenetrative sexual activity,
   and use of vibrators
• Assessing patient's ability to talk with partner(s) and
   coaching for better communication
Core level assessment
• Current sexual function for each sexual response
   domain (desire, arousal, orgasm)
• Presence of sexual pain
• Sexual and romantic relationships (if applicable)
• Distress about and impact of sexual problem
4-Step model
1. Elicit the patient's story
2. Name/reframe attention to sexual problem
   or concern
3. Empathic witnessing
4. Referral or assessment and treatment
Advanced level treatment
Referral to specialist
Advanced level assessment
Referral to specialist
Referral to specialist
No problem/concern detected
Screening
• "Just ask"
• Ubiquity statement screen
• Asking in the context of patient's relationships
• Basic assessment of sexual functioning
Screen all women using any of the following:
FIGURE 1. International Society for the Study of Women’s Sexual Health process of care for the
identiﬁcation of sexual concerns and problems in women.
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Downloadeduring a routine examination, but only 7%
initiated the conversation about sexual
health in that visit.
Women’s sexual function is inﬂuenced
by many biopsychosocial factors. The best
known risk factors are depression, poor
self-assessed health, anxiety, low educational
level, partner sexual problems, sexual abuse,
marital difﬁculties, stress, antidepressant
drug use, poor health, cancer, urinary incon-
tinence, and chronic diseases such as dia-
betes, neurologic diseases, and pain.33-35Mayo Clin Proc. n May 201
d for Anonymous User (n/a) at BS - University of Copenhagen from C
For personal use only. No other uses without permission. Copyright ©CORE AND ADVANCED LEVELS OF
ENGAGEMENT
This POC deﬁnes the role of clinicians in
addressing FSDs for both core and advanced
levels of engagement. Core level skills are pro-
posed as both necessary and sufﬁcient for effec-
tive basic management of womenwith FSD and
are designed with the recognition that some pa-
tients whose sexual problems are identiﬁed will
be referred to sexual health experts. Advanced
level skills describe professional competencies
for clinicians with greater interest in women’s9;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
www.mayoclinicproceedings.org
linicalKey.com by Elsevier on November 14, 2019.
2019. Elsevier Inc. All rights reserved.
"What sexual concerns
do you have?"
"Have your partners
included men, women,
or both?"
"Do you have sexual
concerns that you
would like to discuss
or that have
contributed to lack
of sexual behavior?"
NoYes
Legitimize importance of assessing sexual function;
Normalize as part of usual history and
physical examination
“Are you currently involved in a relationship?”
“Are you sexually active?”
FIGURE 2. Basic screening algorithm for sexual function.
POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENsexual health and sexual medicine specialists
(Figure 1).
Core Level
Screening and Detection: Just Ask. The
framework for addressing women’s sexual
health begins with a mandate to screen for
and detect sexual problems and concerns,
followed by application of the 4-step model
of care discussed later herein, when a sexual
problem or concern is detected. The essen-
tial precondition for addressing FSD is to
detect it. The most fundamental recom-
mendation of this document is simply to ask
about sexual satisfaction, concerns, or
problems.
The Ubiquity Statement Screen for Sexual
Problems and Concerns. This screening
assessment is an effective strategy for
addressing sexual concerns and problems
and can be used to address any awkward, so-
cially undesirable, or stigmatizing topic.3 It
begins with a universalizing and normalizing
ubiquity statement that reassures the patient
that sexual concerns are common, normal,
and even expected.27 For example, “Many
women who have reached menopause, like
you, have concerns about sexual activity.”
This normalizing, universalizing statement is
followed by a closed-ended question, “Do
you?” that acts as a screen. A positive
response is then followed by an open-ended
invitation, “Please, tell me about it,” to
initiate the patient’s narrative. Preceding the
normalizing statement with a declaration
that assessing sexual functioning is an
important part of your usual history and
physical examination with all your patients
can help put patients at ease.
Asking in the Context of Discussing the
Patient’s Relationships. Another strategy is
to inquire about sexual functioning in the
context of a more general discussion about
the patient’s intimate relationships. A broad
open-ended question, such as “How are
things going with your partner/spouse?”
may elicit a comment about sexual concerns,
and this can easily be followed by, “and how
are you and your partner doing in terms of
your sexual relationship?”Mayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Univers
For personal use only. No other uses withouBasic Assessment of Sexual Functio-
ning. To encourage all practitioners to
address sexual function in their patients, it
is important to emphasize that even the
most basic assessment can be useful and
limited to a small number of speciﬁc ques-
tions with minimal time involvement. Three
questions (Figure 2) can sufﬁce for a basic
assessment.36 It is essential to inquire about
the gender of partners. It is important not to
make assumptions about sexual orientation
and behavior, as not all patients identify as
heterosexual or engage exclusively in het-
erosexual sexual behaviors even if they label
themselves as such.Four-Step Model
The 4-step model provides a framework for
engaging with the patient. The 4 steps that
follow screening and detection are as fol-
lows: step 1, elicit the patient’s story; step
2, name and (re)frame attention to the sex-
ual concern or problem; step 3, empathic
witnessing; and step 4, referral or assessment
and treatment.
After a problem is detected, step 1 is to
elicit the story of the problem so that it can
become the focus of attention (step 2).
Empathic witnessing, step 3, reinforces the6/j.mayocp.2019.01.009 847
ity of Copenhagen from ClinicalKey.com by Elsevier on November 14, 2019.
t permission. Copyright ©2019. Elsevier Inc. All rights reserved.
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Downloadeimportance of the problem and validates the
patient’s efforts to address it. The ﬁrst 3 steps
serve as the foundation for recommending
treatment or referral (step 4), which will
often be the outcome of core level
engagement.
Step 1. Elicit the Story. The ﬁrst step is to
elicit a narrative description of the problem
and it’s affect on the patient’s life, emotional
state, and relationships. The goal is to help
the patient discover and describe her
distress, her functional impairment, and the
effect the problem is having on her life.
Patient-Centered Communication: Open-
Ended Questions. The core principles of
patient-centered interviewing are to enable
the patient to express what is important to
her, to recognize her concerns and emotions,
and to allow the interviewer to synthesize
the biopsychosocial depiction of the patient’s
problem.37 Although patients prefer that the
clinician bring up the topic, this interview-
ing style allows the patient to lead parts of
the conversation so that her concerns and
expectations can be heard.37 The most
fundamental element of patient-centered
communication is the use of open-ended
questions to elicit the patient’s story.38
Open-Ended Questions in Ask-Tell-Ask
Sequences. As clinicians elicit the patient’s
story, they also provide new information.
Because clarity regarding the patient’s under-
standing is essential to giving information, it
is critical to ask the patient before telling the pa-
tient something new. With the ﬁrst ask of an
ask-tell-ask sequence the clinician will learn
what the patient knows that is correct,
mistaken, and the most useful information the
patient can understand. The tell is then pur-
posefully constructed to validate the patient’s
correct understanding, correct her mistaken
beliefs, and add the next piece of information
they are ready to hear.
After new information is provided, a second
ask should be used to learn whether the infor-
mationhad the intended effect and to iteratively
continue the ask-tell-ask dialogue. Asking
before telling helps the clinician stay on theMayo Clin Proc. n May 201
d for Anonymous User (n/a) at BS - University of Copenhagen from C
For personal use only. No other uses without permission. Copyright ©thread of the patient’s narrative and avoid
providing information that will be confusing
or to which the patient cannot respond.Bringing the “Pain” Into the Room. The
essential goal of a discussion about a sexual
problem is to elicit the patient’s story and
bring the patient’s emotional distress and
impact of the dysfunction on the patient’s
life into the narrative (bringing the “pain”
into the room). Normalizing emotional
distress and then asking about it, essentially
a reapplication of the ubiquity statement
process focused on emotional distress, is an
effective strategy for accomplishing this.
In summary, the purpose of step 1 is for
the clinician to expose the problem and elicit
the magnitude of distress sufﬁcient to justify
declaring the problem worthy of clinical
attention.
Step 2. Name and (Re)Frame Attention to
the Sexual Problem or Concern. Step 2 con-
sists of naming and framing the problem. It
does not require a precise or reﬁned diag-
nosis at this point in the process. The essen-
tial task is to name and validate the
importance of the sexual problem or concern
in whatever form the patient and clinician
understand it. The clinician can move on
with additional assessment and more speciﬁc
diagnosis, according to their level of engage-
ment, as described in step 4.
Patients may present with a concern that
initially seems to be “the problem” but that
turns out to be due to or accompanied by
another equally or more important problem
that they did not initially mention or that
became apparent through the process of
eliciting the story. This is often the case with
sexual problems or concerns. In these circum-
stances the naming becomes a reframing,
which is accomplished with the following
generic statement: “It seems to me that in
addition to your <initial complaint>, what
you’ve just told me about your <sexual
concern or problem> is just as painful,
important, and worthy of attention.”
Step 3. Empathic Witnessing. A patient-
centered interview intrinsically witnesses9;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
www.mayoclinicproceedings.org
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POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENthe patient’s story, and just listening is an
empathic act. Empathic witnessing by a
clinician is powerful and healing, and this
effect is ampliﬁed when the clinician reﬂects
her or his understanding of the patient’s life
and efforts in words. The strategy is to
commend the patient on her efforts to
address and cope with the issues and chal-
lenges she has revealed in her story.
Empathic witnessing statements may take
the following form: I am impressed with how
committed you are to addressing <the sex-
ual problem and its effects on your rela-
tionship/life> despite how difﬁcult that is.
You are <really beginning to take steps/
determined> to try and solve <this prob-
lem>. Step 3, empathic witnessing, is really
the beginning of treatment for many women,
as the reﬂection and understanding it creates
begin to solve the problem.
Step 4. Referral or Assessment and Treat-
ment. Step 4 offers 2 pathways that can be
used singly or in combination. At this point,
the clinician may choose to either refer to
another clinician or specialist or continue
with further assessment and treatment. As
busy clinicians know, effective management
of any clinical problem takes time. Sexual
problems are not unique in this respect,
but they do deserve time proportional to
the effect that they have on the quality of pa-
tients’ lives. A clinician should deal with the
time required for addressing a sexual prob-
lem in the usual fashion by choosing to
manage it at that appointment or to validate
and schedule a follow-up visit. Whether the
clinician manages the sexual problem herself
or himself or elects to refer, the skills that
follow will help with the execution of efﬁ-
cient history taking and construction of a
therapeutic plan. The options in step 4 allow
clinicians practicing at different levels of
engagement to adjust the intervention to
their skills, comfort, and resources.
The Challenges of Referring for Sexual
Problems. Referral for treatment of sexual
problems can be more challenging than
referral for less emotionally ladened and
potentially embarrassing subjects.39 It isMayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Univers
For personal use only. No other uses withouimportant to make the referral in a way that
does not feel like a rejection, a dismissal, or
an indication that the clinician has been
embarrassed or discomforted. For example,
“I consider sexual health to be important to
your overall health and quality of life and
want you to get the best possible treatment. I
have a colleague who specializes in treating
women’s sexual problems, and I would like
to refer you to her/him so that she/he can
help us improve your sexual health.”
The idea that the problem may need spe-
cial expertise is consistent with its being
important and worthy of attention and ex-
plains the need for expertise that goes
beyond that of the clinician. Patients are
accepting of referral for treatments that
may require more in-depth care than is avail-
able in a general or subspecialty medicine
setting. For example, pointing out that a
therapist may need to meet with the patient
for a longer session and more frequently
than the clinician can accommodate makes
1 reason for a referral clear.
Core Level Assessment of Sexual Function
Setting the Stage for the Sexual
History. Establishing rapport and putting
the patient at ease are critical ﬁrst steps
and help improve overall patient satisfaction.
The clinician sets the tone for the conversa-
tion. If the clinician demonstrates comfort
and ease with sexual terminology and con-
tent, patients are more likely to feel comfort-
able reporting their sexual concerns.
Clinicians may beneﬁt from practicing the
use of explicit sexual terminology (eg,
clitoris, penis) to desensitize themselves to
any embarrassment or hesitation. Blushing
or stammering and avoiding eye contact
sends a negative message. Body language is
important for putting a patient at ease
when discussing sexuality. Sitting is
preferred to standing and gives the impres-
sion that more time has been spent with a
patient, but standing sends the message
that the clinician is wrapping up a visit and
does not really want to address any other is-
sues even if a question is posed.
The best time to obtain a sexual history
or initiate a discussion of sexual concerns6/j.mayocp.2019.01.009 849
ity of Copenhagen from ClinicalKey.com by Elsevier on November 14, 2019.
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visit. This might be in the context of discus-
sing the patient’s relationships, or with a
ubiquity statement, triggered by a relevant
medical or physiologic issue, such as meno-
pause, or during a review of systems. The
discussion should take place in a private
setting, and conﬁdentiality must be ensured.
If possible, the patient should be clothed to
eliminate the embarrassment and vulnera-
bility often experienced when sitting in an
examination gown.
Anticipatingwhether a referral is likely can
help determine the agenda for the initial dis-
cussion. It is important to attend to patient
discomfort and either defer sensitive questions
for a later time or supply alternative responses
for patients if they seem too embarrassed to
provide explicit sexual details.1
Scales and Questionnaires. Self-adminis-
tered questionnaires can be valuable when
addressing a sensitive topic. A waiting
room questionnaire can allow for quick and
easy initial screening of sexual function,
and patients learn early in the ofﬁce visit
that sexual health is of importance to the
clinician and appropriate to discuss. Recom-
mended screeners include the Decreased
Sexual Desire Screener,40 the Brief Proﬁle
of Female Sexual Dysfunction,41 and the
brief screener suggested by Hatzichristou
et al.42 The Female Sexual Function Index is
a well-validated self-report instrument that
assesses 6 domains and has an established
cutoff score of 26.55 for FSD.43
Sexual History: Domains and Questions. A
focused sexual history is likely sufﬁcient to
identify sexual dysfunction and initially
should assess current sexual function for
each sexual response domain (desire,
arousal, orgasm), presence of sexual pain,
sexual/romantic relationship (if applicable),
and distress about and impact of the sexual
problem.
At the core level, a clinician should be
able to identify the most common sexual
problems that cause distress, including low
sexual desire, difﬁculty with sexual arousal,
difﬁculty with orgasm, sexual pain/Mayo Clin Proc. n May 201
d for Anonymous User (n/a) at BS - University of Copenhagen from C
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and relationship problems.
A more speciﬁc sexual dysfunction diag-
nosis (Table 1) requires a thorough bio-
psychosocial sexual assessment and may
require referral to a sexual medicine specialist.
Core Level Treatment
The clinician may initiate many interven-
tions before referral. Empathic delineation
of a problem may be therapeutic and help
the woman to start solving the problem.
Providing education may entail explaining
the sexual adverse effects of a medication,
the changes in sexual function related to
menopause or aging, and the importance of
foreplay/nonpenetrative sexual activies. Cli-
nicians at the core level may recommend
personal lubricants and moisturizers and
may feel competent prescribing local hor-
mone therapy (vaginal estrogen or praster-
one)44,45 for dyspareunia secondary to
genitourinary syndrome of menopause
(GSM) or recommending vibrators to assist
with arousal and orgasm. Assessing the pa-
tient’s ability to talk to their partner(s) about
sexual function and experiences and coach-
ing about better communication are impor-
tant and effective interventions. However,
many sexual health concerns have a bio-
psychosocial etiology and may require a
multidisciplinary treatment team.46 Sexual
health concerns that are predominantly due
to psychological, interpersonal, or sociocul-
tural factors are best treated by a mental
health provider. Sexual pain disorders likely
need a sexual medicine specialist in conjunc-
tion with a pelvic ﬂoor physical therapist.34
Addressing Medical Issues Affecting Sexual
Functioning
Any medical problem or treatment that affects
physical functioning andwell-being can have a
profound effect on sexual function, and clini-
cians can play an important role in recognizing
and treating those effects (Table 2).33,35,47
Oral Contraceptives. Oral contraceptives
have the potential to both improve and
reduce sexual satisfaction.48 When women
using combined hormonal contraceptives9;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
www.mayoclinicproceedings.org
linicalKey.com by Elsevier on November 14, 2019.
2019. Elsevier Inc. All rights reserved.
TABLE 2. Contributing Factors to Sexual Dysfunction33,35,47
Medical conditions
Cardiovascular disease
Diabetes
Thyroid disease
Chronic pain
Urinary incontinence
Spinal cord injury
Multiple sclerosis
Neuromuscular disorders
Prolactinoma
Malignancy/treatment: mastectomy, gynecologic/colorectal surgery, pelvic radiation
Gynecologic disorders: pelvic organ prolapse, endometriosis, ﬁbroids, vulvar
dermatoses, vulvodynia/vestibulodynia
Psychiatric disorders
Medications
Anticonvulsants: carbamazepine, phenytoin, primidone
Cardiovascular medications: amiodarone, b-blockers, calcium channel blockers,
clonidine, digoxin, hydrochlorothiazide, statins, methyldopa
Hormonal agents: antiandrogens (ﬂutamide, spironolactone), gonadotropin-
releasing hormone agonists, combined hormonal contraceptives, tamoxifen,
aromatase inhibitors
Pain medication: nonsteroidal anti-inﬂammatory drugs, opioids
Psychotropic medications: antipsychotics, benzodiazepines, lithium, selective
serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors,
tricyclic antidepressants
POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENhave low desire, pain, or decreased arousal
or orgasm, switching to a different contra-
ceptive method may be helpful.49
Depression and Antidepressant Medi-
cation. Many women with depression are
treated with selective serotonin reuptake in-
hibitors or serotonin and norepinephrine
reuptake inhibitors. Both the primary disease
and its pharmacologic therapy can have a sig-
niﬁcant effect on libido and sexual response.
For treatment-emergent sexual dysfunction,
strategies include dose reduction, drug
discontinuation or switching, and augmen-
tation or use ofmedicationwith a lower rate of
adverse effects. Adding or switching to
bupropion may help with this problem.50
Behavioral interventions such as exercise
before sex, scheduling sexual activity, or
vibratory stimulation may also be useful.50
Other Medications. Other medications,
including tamoxifen, aromatase inhibitors,
gonadotropin-releasing hormone agonists,
antihypertensives, and antihistamines, may
adversely affect sexual function. Clinicians
should review the role of medication and
consider modifying drug regimens when
treating sexual dysfunction.33
Genitourinary Syndrome of Meno-
pause. Genitourinary syndrome of meno-
pause affects at least 50% of postmenopausal
women. Many women experience dyspareu-
nia and may not realize that decreased libido
or orgasmic difﬁculties may be secondary to
their vulvovaginal atrophy.51 Treating GSM
can alleviate this problem.52
Partner Sexual Problems. Women’s sexual
health may be adversely affected by their
partners’ sexual dysfunction (eg, erectile
dysfunction, premature ejaculation, HSDD).
Assessment of the partners’ physical health
and sexual function is part of a more detailed
assessment of patients’ sexual health.53The Role of Physical Examination and Lab-
oratory Tests
Assessment of vaginal and vulvar pain
should include a focused history andMayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Univers
For personal use only. No other uses withouexamination to identify potential causes or
contributing factors, including infectious, in-
ﬂammatory, neoplastic, neurologic, trau-
matic, iatrogenic, and hormonal factors. A
pelvic examination including a vulvovaginal
examination is important for women with
pelvic pain. It may help locate the source
of the pain, including vulvar skin conditions
and GSM in postmenopausal women.
Referral to a specialist (gynecology, sexual
medicine, dermatology) is usually indicated
when the examination does not clearly estab-
lish the source of sexual pain.54
Laboratory testing (eg, vaginal pH)may be
helpful but is usually not necessary. Testing
for sexually transmitted infections and other
vaginal pathogens may be useful in assessing
sexual pain. Other laboratory tests, such as
thyroid function and prolactin levels, may be
indicated based on the patient’s symptoms or
ﬁndings on physical examination.55
Advanced Level Skills
Clinicians interested in more intensive
engagement in the assessment and treatment6/j.mayocp.2019.01.009 851
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can incorporate more advanced skills in tak-
ing a sexual history, diagnosing FSD, and
initiating treatment.
Sexual History. If the patient reports a sexual
concern, it is important to inquirewhether the
problem is lifelong or acquired and to explore
whether it is generalized or situational (eg,
present during partnered sexual activity but
not with self-stimulation). Answers to these
questions can help the clinician better deter-
mine whether the patient’s sexual concerns
are primarily biologically or psychologically
based.
Sensitivity to and skill in discussing reli-
gious background, cultural and environ-
mental factors, and attitudes toward and
style of communication about sexuality in
the patient’s family of origin can all
contribute to a more effective sexual history.
Assessing Sexual Function Using the Sexual
Response Cycle. Clinicians engaged at the
advanced skill level should perform a more
thorough assessment of the patient’s sexual
functioning:
DesiredQuestions should focus on fre-
quency of interest in engaging in any type
of sexual activity (eg, self-stimulation, oral
sex) and how the level of desire may be
affecting her relationships.56 Women may
report not having spontaneous desire (ie, in-
terest/fantasies that are not in response to
external sexual stimuli) but may report hav-
ing responsive desire (ie, interest/willingness
to engage when approached for sexual activ-
ity or being sexually stimulated).34
ArousaldClinicians should assess sexual
arousal by asking about difﬁculties with
lubrication and diminished genital engorge-
ment and sensation. They should also ask
whether there is sufﬁcient sexual stimulation
and about the relationship between arousal
and sexual practices, partner(s), and
situations.
OrgasmdClinicians should learn about
the patient’s frequency of orgasm, ease and
methods of achieving orgasm, and intensity
of and satisfaction with orgasm. It is impor-
tant to explore whether the woman hasMayo Clin Proc. n May 201
d for Anonymous User (n/a) at BS - University of Copenhagen from C
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ﬁcient sexual stimulation.
PaindIn addition to learning whether
the patient is experiencing any genitopelvic
pain, clinicians should inquire about
whether the pain is constant (unprovoked)
or only during penetrative activities or geni-
tal contact (provoked), whether it is superﬁ-
cial or deep, the relationship between the
occurrence of pain and arousal, and context.
Diagnosis of FSD. Regarding low sexual
desire, distinctions should be made between
the presence (or absence) of responsive vs
spontaneous desire; and assessments of
dysfunction should be framed with an un-
derstanding that responsive desire may be
normal and satisfying. Clinicians should
also determine whether low sexual desire is
due to a medical, psychological, sociocul-
tural, or relational problem. The relation-
ship(s) between dysfunctions related to
desire, arousal, and orgasm and pain (if pre-
sent) should be established.
Advanced level clinicians should also be
aware of important but less common FSDs,
such as persistent genital arousal disorder,
pleasure dissociative orgasm disorder, and fe-
male orgasmic illness syndrome (Table 1).Comorbid Behavioral Health and Psychiatric
Problems
When serious psychosocial problems are
encountered, the advanced level clinician
should apply the 4-step model of care to
identify, reframe, empathically witness,
and then refer patients to sex therapists or
other mental health professionals. Past or
current sexual abuse, body image concerns,
psychiatric conditions, trauma, and conﬂict
in relationship(s) are commonly encoun-
tered in patients with sexual problems. Pa-
tients should be screened for commonly
occurring mental health issues, including
depression, anxiety, and substance abuse
disorders. The presence of unresolved sex-
ual trauma; lifelong sexual problems; or
ongoing intrapersonal, interpersonal, and
sociocultural problems should also prompt
referral to a sexual or mental health
specialist.579;94(5):842-856 n https://doi.org/10.1016/j.mayocp.2019.01.009
www.mayoclinicproceedings.org
linicalKey.com by Elsevier on November 14, 2019.
2019. Elsevier Inc. All rights reserved.
TABLE 3. Treatments for Female Sexual Dysfunctions34,36,52,55
Medication category Product name Formulation Indication
Pharmacologic treatments
Local vaginal estrogens Estradiol or CEE cream
(Estrace, Premarin)
Estradiol vaginal tablet
(Vagifem, Yuvafem)
Estradiol vaginal gel cap
(Imvexxy)
Estradiol vaginal ring (Estring)
Cream
Vaginal tablet
Vaginal gel cap
Vaginal ring
Genitourinary syndrome of
menopause
Selective estrogen receptor
modulator
Ospemiphene (Osphena) Oral tablet Genitourinary syndrome of
menopause
DHEA Prasterone (Intrarosa) Vaginal suppository Genitourinary syndrome of
menopause
Testosterone (Not FDA approved
in women, approved in countries
outside the United States)
Testosterone Transdermal cream
or gel
Hypoactive sexual desire
disorder
Serotonin agonist/antagonist Flibanserin (Addyi) Oral tablet Hypoactive sexual desire
disorder
Nonpharmacologic treatments
Lubricants Multiple products Water-based
Silicone-based
Hybrid (water- and
silicone-based)
Oil-based
Used as needed for to reduce
friction and enhance
comfort with sexual activity
Moisturizers Multiple products NA Used regularly for maintenance
of vulvar/vaginal moisture
Sex therapy NA NA Helpful for all FSD diagnoses
Pelvic ﬂoor physical therapy NA NA For treatment of pelvic ﬂoor
dysfunction
Mechanical devices Vibrators
Clitoral vacuum device (Eros)
NA Used to enhance vulvar,
clitoral,
and vaginal stimulation
Vaginal lasers (FDA cleared, but no speciﬁc
indication for genitourinary syndrome of
menopause)
Carbon dioxide fractional
lasers
Erbium YAG lasers
NA Genitourinary syndrome of
menopause
CEE ¼ conjugated equine estrogen; FDA ¼ Food and Drug Administration; FSD ¼ female sexual dysfunction; NA ¼ not applicable; YAG ¼ yttrium-aluminum-garnet.
POC FOR IDENTIFICATION OF SEXUAL PROBLEMS IN WOMENAdvanced Level Treatment
In-depth discussion of advanced level treat-
ment is beyond the scope of this POC.
More complex treatments that are within
the scope of practice of the well-trained
clinician are listed in Table 3. Advanced
level pharmacotherapy includes the use of
ospemifene in addition to the use of
vaginal hormone therapy for GSM,58 ﬂiban-
serin for generailized acquired HSDD in
premenopausal women,59,60 and off-label
use of ﬂibanserin61 or transdermal testos-
terone in postmenopausal women with
HSDD.62 Nonpharmacologic treatmentsMayo Clin Proc. n May 2019;94(5):842-856 n https://doi.org/10.101
www.mayoclinicproceedings.org
Downloaded for Anonymous User (n/a) at BS - Univers
For personal use only. No other uses withoumay include devices such as the clitoral
vacuum device or laser63,64 and the inte-
gration of sex therapy or pelvic ﬂoor phys-
ical therapy.
Establishing a robust referral network is
helpful; possible referrals may include a vari-
ety of specialties, such as gynecology or uro-
gynecology with a special interest in sexual
health, sexual medicine, sex therapy, and
pelvic ﬂoor physical therapy. Professional
organizations are valuable resources for in-
formation and networks of providers
(Supplemental Appendix, available online
at http://www.mayoclinicproceedings.org).6/j.mayocp.2019.01.009 853
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This ISSWSH POC provides a paradigm for
the clinician to identify sexual problems in
women and provide basicmanagement strate-
gies, taking into account the biological, psy-
chological, sociocultural, and relationship
factors that may be playing a role. The goal
of identiﬁcation is to provide education, man-
agement, and referral when appropriate for
women with sexual concerns or problems.ACKNOWLEDGMENT
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